Bottom line
HLHIX vs XLV: the short answer
HLHIX (Virtus KAR Health Sciences Fund) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both mutual funds.
But XLV is far broader, holding 65 positions to 24 for HLHIX, so beyond the top names it adds exposure HLHIX doesn't have.
XLV is cheaper at 0.08% vs 1.05% — a difference of $97 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +3.8% for HLHIX.
Updated Nov 19, 2026
HLHIX vs XLV side by side
| HLHIX | XLV | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Virtus | SPDR (State Street) |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.05% | 0.08% |
| Annual cost per $10k | $105 | $8 |
| 10-yr cost on $10k (prospectus) | $1,367 | $103 |
| Max front load | 0% | None |
| 12b-1 fee | 0% | 0.02% |
| 1-yr return | +7.6% | +14.5% |
| 5-yr return (annualized) | +3.8% | +8.1% |
| 10-yr return (annualized) | +7.1% | +9.8% |
| Best quarter | +16.5% | +14.5% |
| Worst quarter | −11.8% | −12.7% |
| Net assets (fund) | $91.7M | $40.6B |
| Number of holdings | 24 | 65 |
| Portfolio turnover | 13% | 2% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | HLHIX | XLV | Difference |
|---|---|---|---|
| 2025 | +7.6% | +14.5% | −6.9% |
| 2024 | −2.0% | +2.5% | −4.5% |
| 2023 | +2.8% | +2.0% | +0.9% |
| 2022 | −11.6% | −2.1% | −9.5% |
| 2021 | +25.7% | +25.9% | −0.2% |
| 2020 | +14.1% | +13.3% | +0.8% |
Source: Fund prospectus bar charts
Holdings overlap
11 of HLHIX's top 24 holdings also appear in XLV's top 25.
| Holding | HLHIX | XLV |
|---|---|---|
| Eli Lilly & Company | 14.84% | 16.51% |
| Abbvie Inc | 5.52% | 7.74% |
| Vertex Pharmaceuticals Inc | 5.32% | 2.19% |
| Merck & Company Inc | 5.06% | 5.52% |
| Unitedhealth Group Inc | 4.65% | 6.57% |
| Mckesson Corp | 4.57% | 1.58% |
| Intuitive Surgical Inc | 3.89% | 2.45% |
| Amgen Inc | 3.85% | 3.40% |
| Thermo Fisher Scientific Inc | 3.65% | 3.24% |
| Danaher Corp | 3.37% | 2.09% |
| Regeneron Pharmaceuticals Inc | 2.90% | 1.08% |
Source: SEC Form N-PORT
HLHIX top 10
- Eli Lilly & Company — 14.84%
- West Pharmaceutical Services Inc — 5.92%
- Abbvie Inc — 5.52%
- Vertex Pharmaceuticals Inc — 5.32%
- Merck & Company Inc — 5.06%
- Unitedhealth Group Inc — 4.65%
- Mckesson Corp — 4.57%
- Mettler-toledo International Inc — 3.99%
- Intuitive Surgical Inc — 3.89%
- Amgen Inc — 3.85%
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
FAQ
What is the difference between HLHIX and XLV?
Which is cheaper, HLHIX or XLV?
Should I own both HLHIX and XLV?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.